Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-κB pathway

References

• Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661–666.
   PubMed Web of Science ®Google Scholar
• Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007;282:36275–36282.
   PubMed Web of Science ®Google Scholar
• Wang X, Zheng W, Xie JW, Wang T, Wang SL, Teng WP, Wang ZY. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 2010;5:46–58.
   PubMed Web of Science ®Google Scholar
• Burdo JR, Chen Q, Calcutt NA, Schubert D. The pathological interaction between diabetes and presymptomatic Alzheimer's disease. Neurobiol Aging 2009;30:1910–1917.
   PubMed Web of Science ®Google Scholar
• Podell BK, Ackart DF, Kirk NM, Eck SP, Bell C, Basaraba RJ. Non-diabetic hyperglycemia exacerbates disease severity in Mycobacterium tuberculosis infected guinea pigs. PLoS One 2012;7:e46824.
   Google Scholar
• Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi S. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001;31:513–520.
   PubMed Web of Science ®Google Scholar
• Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001;888:256–262.
   PubMed Web of Science ®Google Scholar
• Alexiou P, Chatzopoulou M, Pegklidou K, Demopoulos VJ. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 2010;17:2232–2252.
   PubMed Web of Science ®Google Scholar
• Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907–913.
   PubMed Web of Science ®Google Scholar
• Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 2007;85:1194–1204.
   Google Scholar
• Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007;56:211–216.
   PubMed Web of Science ®Google Scholar
• Kroner Z. The relationship between Alzheimer's disease and diabetes. Type 3 diabetes? Altern Med Rev 2009;14:373–379.
   PubMedGoogle Scholar
• Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 2012;123:224–235.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003;23:129–134.
   PubMedGoogle Scholar
• Munch G, Deuther-Conrad W, Gasic-Milenkovic J. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease–a target for neuroprotective treatment strategies? J Neural Transm Suppl 2002;62:303–307.
   Google Scholar
• Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, Federici A. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 2005;1043:710–717.
   PubMed Web of Science ®Google Scholar
• Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 2001;22:397–402.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008;14:973–978.
   PubMed Web of Science ®Google Scholar
• Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2009;32:763–777.
   PubMed Web of Science ®Google Scholar
• Kuhla B, Loske C, Garcia De Arriba S, Schinzel R, Huber J, Munch G. Differential effects of “Advanced glycation endproducts” and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 2004;111:427–439.
   PubMed Web of Science ®Google Scholar
• Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Munch G. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 2000;267:4171–4178.
   PubMedGoogle Scholar
• Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010;106:842–853.
   PubMed Web of Science ®Google Scholar
• Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier. implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009;8:16–30.
   PubMed Web of Science ®Google Scholar
• Lue LF, Walker DG, Jacobson S, Sabbagh M. Receptor for advanced glycation end products. its role in Alzheimer's disease and other neurological diseases. Future Neurol 2009; 4:167–177.
   PubMedGoogle Scholar
• Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease. a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 2009; 16:833–843.
   PubMed Web of Science ®Google Scholar
• Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997;272:16498–16506.
   PubMed Web of Science ®Google Scholar
• Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:19919–19924.
   PubMed Web of Science ®Google Scholar
• Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation. distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 2005;7:395–403.
   PubMed Web of Science ®Google Scholar
• Smale ST. Hierarchies of NF-kappaB target-gene regulation. Nat Immunol 2011;12:689–694.
   PubMed Web of Science ®Google Scholar
• Kaltschmidt B, Ndiaye D, Korte M, Pothion S, Arbibe L, Prullage M, Pfeiffer J, Lindecke A, Staiger V, Israel A, Kaltschmidt C, Memet S. NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol 2006;26:2936–2946.
   PubMed Web of Science ®Google Scholar
• Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 2010;33: 196 e113–127.
   Web of Science ®Google Scholar
• Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y, Song W. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 2011;1–14.
   Web of Science ®Google Scholar
• Chami L, Buggia-Prevot V, Duplan E, Delprete D, Chami M, Peyron JF, Checler F. Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem 2012;287:24573–24584.
   PubMed Web of Science ®Google Scholar
• Zhou W, Cai F, Li Y, Yang GS, O'Connor KD, Holt RA, Song W. BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease. J Mol Neurosci 2010;42:127–133.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 2009;23:2639–2649.
   PubMed Web of Science ®Google Scholar